Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Egyesült ÁllamokFázis nélkül

Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairment and Insulin Resistance

A legfontosabb adatok

Ki végzi
SF Research Institute, Inc.
Hol
San Francisco (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Toboroz
Résztvevők
140 fő, tervezett
Kezdés
2026. jan. 29.
Tervezett befejezés
2026. ápr. 29.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Sabroxy®
  • Placebo
A regiszteradat frissítve
2026. január 28.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with mild memory and thinking problems and insulin resistance. People take Sabroxy® or a placebo once a day for 8 weeks.

Életkor
40 to 80 years, in two groups: 40 - 60 and 61 - 80.
Nem
Men and women can join.
A betegség stádiuma
Mild cognitive impairment (MoCA score less than 26) and insulin resistance. People must be in good general health.
Korábbi kezelés
People cannot join if they regularly take medicines or supplements that affect blood sugar. They also cannot join if they used corticosteroids in the past 4 weeks, or started a long-term medicine in the last 2 months.
Biomarker vagy leletérték
HOMA-IR value ≥ 2.0 to < 4.0 and fasting glucose 100 to 135 mg/dL (5,6–7,5 mmol/L) at screening.

A részvétel fő kizáró okai

  • Pregnant, breastfeeding, or planning a pregnancy
  • Immune system disorders, HIV, organ transplant, or medicines that weaken the immune system
  • Skin cancer in the past 5 years
  • Uncontrolled disease such as diabetes, asthma, epilepsy, high blood pressure or thyroid disease
  • Heart or blood vessel event in the last 3 months, or severe depression

A regiszter feltételei, szó szerint

Mind a 19 feltétel megnézéseKevesebb

Ki vehet részt

  • Female or male, adults grouped by age as follows 2 groups of 70 patients each (35 active and 35 placebo ); GROUP 1 = aged 40 - 60, and; GROUP 2 = aged 61 - 80
  • In good general health
  • Screening HOMA-IR value ≥ 2.0 to < 4.0
  • Screening fasting glucose 100 to 135 mg/dL
  • Screening MoCA less than 26

Ki nem vehet részt

  • Having a history of immunosuppression/immune deficiency disorders (including HIV infection, it has been AIDS, multiple sclerosis, Crohn's disease, rheumatoid arthritis), organ transplant (heart, kidney, etc.), or currently using oral or systemic immunosuppressive medications and biologics (e.g., azathioprine, belimumab, Cimzia®, Cosentyx®, cyclophosphamide, cyclosporine, Enbrel®, Humira®, Imuran®, Kineret®, mycophenolate mofetil, methotrexate, Orencia®, prednisone, Remicade®, Rituxan®, Siliq™, Simponi®, Stelara®, Taltz®) and/or undergoing radiation or chemotherapy as determined by study documentation
  • Currently using or having regularly used corticosteroids (systemic or topical, not nasal or ocular) within the past 4 weeks (including but not limited to betamethasone, clobetasol, desoximetasone, diflorasone, fluocinonide, halcinonide, and halobetasol)
  • Having started a long-term medication within the last 2 months
  • Having participated in any other clinical trial that evaluates or applies interventions to the same body system, organ, or condition being studied in this trial within 12 weeks prior to the screening visit at SFRI or another research facility or doctor's office
  • Having been diagnosed with known allergies to any ingredients in the study product
  • Relevant history or presence of any medical disorder potentially interfering with this study (e.g., malabsorption, chronic gastrointestinal diseases, severe depression, cardiovascular disease occurrence within the last 3 months, etc.),
  • Having a history of skin cancer within the past 5 years
  • Having a disease such as asthma, diabetes, epilepsy, hypertension, hyperthyroidism, or hypothyroidism that is not controlled by diet or medication. Individuals having multiple health conditions may be excluded from participation even if the conditions are controlled by diet, medication, etc
  • Note - Medications for treatment of chronic diseases that do not affect the metabolism of the study product will be permitted and will be judged individually regarding interference with the study by an investigator
  • Regular intake of medications or supplements known to affect glucose tolerance
  • Breastfeeding, pregnant, or planning to become pregnant during the study, according to the subject's self-report
  • Having a pregnant partner or a partner who is planning to become pregnant during the study period or is unwilling or unable to use an acceptable method of contraception
  • Having planned surgeries or invasive medical procedures during the study. Non-invasive medical procedures or surgeries will be reviewed for their impact on the study outcome and acceptability by the Investigator or designee
  • Currently participating in any other clinical trial at SFRI or another research facility or doctor's office

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 40 és 80 év között vagy?

Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.

  • San Francisco Research InstituteSan Francisco, Egyesült ÁllamokContact: Khaleeq RehmanRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

This randomized, double-blind, placebo-controlled, 8-week clinical trial is designed to evaluate the effects of Sabroxy®, a standardized extract of Oroxylum indicum bark, on insulin resistance and cognitive function in adults with mild cognitive impairment and insulin resistance.

A teljes eredeti leírásKevesebb

A total of 120 participants (men and women, aged 40-80 years) who are non-smokers, with fasting glucose levels between 100-135 mg/dL, HOMA-IR value ≥ 2.0 to < 4.0, and a Montreal Cognitive Assessment (MoCA) score below 26, will be enrolled. Eligible participants will be randomized (1:1) to receive either Sabroxy® (250 mg with 5 mg BioPerine®) or placebo, administered orally once daily for 8 weeks.

The primary endpoint is the change in insulin resistance from baseline to Week 8, assessed using the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR).

The secondary endpoints include changes in:

Cognitive performance, assessed using the Immediate Word Recall, Numeric Working Memory, Cognitive Failures Questionnaire (CFQ), and Montreal Cognitive Assessment (MoCA).

Biomarkers of metabolic and neuronal function, including Brain-Derived Neurotrophic Factor (BDNF), high-sensitivity C-reactive protein (hs-CRP), fasting insulin, fasting glucose, and phosphorylated tau/amyloid beta (p-Tau/Aβ) ratio.

Safety will be assessed through adverse event monitoring, vital signs, and routine clinical laboratory tests.

The study will be conducted at a single site, San Francisco Research Institute (USA), in compliance with the Declaration of Helsinki, ICH-GCP guidelines, and 21 CFR Part 312 (where applicable).

This study seeks to generate clinical evidence supporting the potential of Sabroxy® supplementation to improve glucose tolerance, reduce inflammation, and enhance cognitive function in individuals with early metabolic and neurocognitive dysfunctions.

A vizsgálat 2 csoportja

  • Dietary Supplement (Sabroxy®)Már használt kezelés, összehasonlításként

    Subjects are to take two capsules with water in the am.

    Kezelés: Sabroxy®

  • Placebo (Inactive capsule)Placebo, összehasonlításként

    Subjects are to take two capsules with water in the am.

    Kezelés: Placebo

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
An 8-week Study Evaluating the Effects of a Dietary Supplement (Sabroxy®) on Insulin Resistance and Cognitive Function in Subjects With Mild Cognitive Impairment and Insulin Resistance
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
Kérdések a feltételekről
Forrás: NCT07220694: ki vehet részt
A regiszteradat frissítve
2026. január 28.